Ethacrynic acid
As of the edition of 20 October 2026, Ethacrynic acid is a small molecule: marketed, first approved in 1968 (CA); acts on SLC12A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Edecrin
- First approved
- 31 December 1968 (CA)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- Bausch Health
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Eye; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC12A1 | Solute carrier family 12 member 1 | Q13621 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bausch Health | Acquired holder | 1968 to now |
| Merck & Co. | Applicant |